FUSTER
ET AL., ACC/AHA/ESC GUIDELINES FOR THE MANAGEMENT OF
PATIENTS WITH ATRIAL FIBRILLATION
J Am Coll Cardiol 2001;38:1266i-1xx
ACC/AHA/ESC
Guidelines for the Management of Patients with Atrial
Fibrillation
References
1.
Bellet S. Clinical Disorders of the Heart Beat.
3rd ed. Philadelphia: Lea & Febiger, 1971.
2.
Prystowsky EN, Katz AM. Atrial fibrillation. In: Topol,
ES, editor. Textbook of Cardiovascular Medicine.
Philadelphia: Lippincott-Raven, 1998:1827-61.
3.
Levy S, Breithardt G, Campbell RW, et al, for the Working
Group on Arrhythmias of the European Society of Cardiology.
Atrial fibrillation: current knowledge and recommendations
for management. Eur Heart J 1998;19:1294-320.
4.
Jais P, Haissaguerre M, Shah DC, et al. A focal source
of atrial fibrillation treated by discrete radiofrequency
ablation. Circulation 1997;95:572-6.
5.
Allessie MA, Konings KT, Kirchhof CJ. Mapping of atrial
fibrillation. In: Olsson SB, Allessie MA, Campbell RW,
eds. Atrial Fibrillation: Mechanisms and Therapeutic
Strategies. Armonk, NY: Futura Pub, 1994:37-49.
6.
Levy S, Novella P, Ricard P, Paganelli F. Paroxysmal
atrial fibrillation: a need for classification. J
Cardiovasc Electrophysiol 1995;6:69-74.
7.
Sopher SM, Camm AJ. Therapy for atrial fibrillation:
control of the ventricular response and prevention of
recurrence. Coron Artery Dis 1995;6:106-14.
8.
Levy S. Classification system of atrial fibrillation.
Curr Opin Cardiol 2000;15:54-7.
9.
Gallagher MM, Camm J. Classification of atrial fibrillation.
Am J Cardiol 1998;82:18N-28N.
10.
Kopecky SL, Gersh BJ, McGoon MD, et al. The natural
history of lone atrial fibrillation: a population-based
study over three decades. N Engl J Med 1987;317:669-74.
11.
Feinberg WM, Cornell ES, Nightingale SD, et al, for
the Stroke Prevention in Atrial Fibrillation Investigators.
Relationship between prothrombin activation fragment
F1.2 and international normalized ratio in patients
with atrial fibrillation. Stroke 1997;28:1101-6.
12.
Ostranderld JR, Brandt RL, Kjelsberg MO, Epstein FH.
Electrocardiographic findings among the adult population
of a total natural community, Tecumseh, Michigan. Circulation
1965;31:888-98.
13.
Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic
atrial fibrillation [published erratum appears in Lancet
1987;1:878]. Lancet 1987;1:526-9.
14.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as
an independent risk factor for stroke: the Framingham
Study. Stroke 1991;22:983-8.
15.
Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE,
Rautaharju PM. Prevalence of atrial fibrillation in
elderly subjects (the Cardiovascular Health Study).
Am J Cardiol 1994;74:236-41.
16.
Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary
heart disease and atrial fibrillation: the Framingham
Study. Am Heart J 1983;106:389-96.
17.
Psaty BM, Manolio TA, Kuller LH, et al. Incidence of
and risk factors for atrial fibrillation in older adults.
Circulation 1997;96:2455-61.
18.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed
atrial fibrillation in adults: national implications
for rhythm management and stroke prevention: the AnTicoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) Study.
JAMA 2001;285:2370-5.
19.
Evans W, Swann P. Lone auricular fibrillation. Br
Heart J 1954;16:189-94.
20.
Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics
and prognosis of lone atrial fibrillation: 30-year follow-up
in the Framingham Study. JAMA 1985;254:3449-53.
21.
Levy S, Maarek M, Coumel P, et al, for the College of
French Cardiologists. Characterization of different
subsets of atrial fibrillation in general practice in
France: the ALFA study. Circulation 1999;99:3028-35.
22.
Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind
placebo-controlled trial of digoxin in symptomatic paroxysmal
atrial fibrillation. Circulation 1999;99:2765-70.
23.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation:
a major contributor to stroke in the elderly: the Framingham
Study. Arch Intern Med 1987;147:1561-4.
24.
Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE.
The natural history of atrial fibrillation: incidence,
risk factors, and prognosis in the Manitoba Follow-Up
Study. Am J Med 1995;98:476-84.
25.
Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger
AJ, Wolf PA. Independent risk factors for atrial fibrillation
in a population-based cohort: the Framingham Heart Study.
JAMA 1994;271:840-4.
26.
Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril
reduces the incidence of atrial fibrillation after acute
myocardial infarction in patients with left ventricular
dysfunction. Circulation 1999;100:376-80.
27.
Crijns HJ, Tjeerdsma G, De Kam PJ, et al. Prognostic
value of the presence and development of atrial fibrillation
in patients with advanced chronic heart failure. Eur
Heart J 2000;21:1238-45.
28.
Risk factors for stroke and efficacy of antithrombotic
therapy in atrial fibrillation: analysis of pooled data
from five randomized controlled trials [published erratum
appears in Arch Intern Med 1994;154:2254]. Arch Intern
Med 1994;154:1449-57.
29.
Hart RG, Halperin JL. Atrial fibrillation and thromboembolism:
a decade of progress in stroke prevention. Ann Intern
Med 1999;131:688-95.
30. Feinberg WM, Seeger JF, Carmody
RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features
of asymptomatic cerebral infarction in patients with
nonvalvular atrial fibrillation. Arch Intern Med
1990;150:2340-4.
31. Kempster PA, Gerraty RP, Gates
PC. Asymptomatic cerebral infarction in patients with
chronic atrial fibrillation. Stroke 1988;19:955-7.
32.
Stroke Prevention in Atrial Fibrillation Study: final
results. Circulation 1991;84:527-39.
33.
Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted
C, Boysen G. Silent cerebral infarction in chronic atrial
fibrillation. Stroke 1987;18:1098-100.
34.
Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic
assessment of chronic atrial fibrillation and risk of
stroke: the Framingham Study. Neurology 1978;28:973-7.
35.
Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell
L, Cohn JN, for the V-HeFT VA Cooperative Studies Group.
The influence of atrial fibrillation on prognosis in
mild to moderate heart failure: the V-HeFT Studies.
Circulation 1993;87:VI-102--10.
36.
Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw
MA, Stevenson LW. Atrial fibrillation is associated
with an increased risk for mortality and heart failure
progression in patients with asymptomatic and symptomatic
left ventricular systolic dysfunction: a retrospective
analysis of the SOLVD trials: Studies of Left Ventricular
Dysfunction. J Am Coll Cardiol 1998;32:695-703.
37.
Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart
RG. Prevalence, age distribution, and gender of patients
with atrial fibrillation: analysis and implications.
Arch Intern Med 1995;155:469-73.
38.
Bharti S, Lev M. Histology of the normal and diseased
atrium. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation:
Mechanism and Management. New York: Raven
Press, 1992:15-39.
39.
Guiraudon CM, Ernst NM, Yee R, Lein GJ. The pathology
of drug resistant lone atrial fibrillation in eleven
surgically treated patients. In: Kingma JH, Van Hernel
NM, Lie KI, eds. Atrial Fibrillation: A Treatable
Disease? Dordrecht: Kluwer Academic Pub, 1992:41-57.
40.
Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo
MA, Maseri A. Histological substrate of atrial biopsies
in patients with lone atrial fibrillation. Circulation
1997;96:1180-4.
41.
Dittrich HC, Pearce LA, Asinger RW, et al, for the Stroke
Prevention in Atrial Fibrillation Investigators. Left
atrial diameter in nonvalvular atrial fibrillation:
an echocardiographic study. Am Heart J 1999;137:494-9.
42.
Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial
fibrillation by heart failure in dogs: atrial remodeling
of a different sort. Circulation 1999;100:87-95.
43.
Maixent JM, Paganelli F, Scaglione J, Levy S. Antibodies
against myosin in sera of patients with idiopathic paroxysmal
atrial fibrillation. J Cardiovasc Electrophysiol
1998;9:612-7.
44.
Moe GK, Abildskov JA. Atrial fibrillation as a self
sustaining arrhythmia independent of focal discharge.
Am Heart J 1959;58:59-70.
45.
Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij
MJ. Length of excitation wave and susceptibility to
reentrant atrial arrhythmias in normal conscious dogs.
Circ Res 1988;62:395-410.
46.
Scherf D, Romano FJ, Terranova R. Experimental studies
on auricular flutter and auricular fibrillation. Am
Heart J 1948;36:241.
47.
Scherf D, Schaffer AI, Blumfeld S. Mechanism of flutter
and fibrillation. Arch Intern Med 1953;91:241-51.
48.
Haissaguerre M, Jais P, Shah DC, et al. Spontaneous
initiation of atrial fibrillation by ectopic beats originating
in the pulmonary veins. N Engl J Med 1998;339:659-66.
49.
Chen SA, Tai CT, Yu WC, et al. Right atrial focal atrial
fibrillation: electrophysiologic characteristics and
radiofrequency catheter ablation. J Cardiovasc Electrophysiol
1999;10:328-35.
50. Spach MS, Barr RC, Jewett PH. Spread
of excitation from the atrium into thoracic veins in
human beings and dogs. Am J Cardiol 1972;30:844-54.
51.
Nathan H, Eliakim M. The junction between the left atrium
and the pulmonary veins: an anatomic study of human
hearts. Circulation 1966;34:412-22.
52.
Zipes DP, Knope RF. Electrical properties of the thoracic
veins. Am J Cardiol 1972;29:372-6.
53.
Cheung DW. Electrical activity of the pulmonary vein
and its interaction with the right atrium in the guinea-pig.
J Physiol (Lond) 1981;314:445-56.
54.
Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced
arrhythmia. Nature 1981;294:582-4.
55.
Paes DA, Bohm CM, de Paula CM, Paes DC. The cardiac
muscle in the pulmonary vein of the rat: a morphological
and electrophysiological study. J Morphol 1975;145:409-33.
56.
Moe GK, Abildskov JA. Observations on the ventricular
dysrhythmia associated with atrial fibrillation in the
dog heart. Circ Res 1964;4:447-60.
57.
Allessie MA, Lammers WJ, Bonke FI, Hollen J. Experimental
evaluation of Moe's multiple wavelet hypothesis of atrial
fibrillation. In: Zipes DP, Jalife J, eds. Cardiac
Electrophysiology and Arrhythmias. New York: Grune
& Stratton, 1985:265-76.
58.
Cox JL, Canavan TE, Schuessler RB, et al. The surgical
treatment of atrial fibrillation, II: intraoperative
electrophysiologic mapping and description of the electrophysiologic
basis of atrial flutter and atrial fibrillation. J
Thorac Cardiovasc Surg 1991;101:406-26.
59.
Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn
OC, Allessie MA. High-density mapping of electrically
induced atrial fibrillation in humans. Circulation
1994;89:1665-80.
60.
Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife
J. Spatiotemporal periodicity during atrial fibrillation
in the isolated sheep heart. Circulation 1998;98:1236-48.
61.
Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite
mapping studies during induced atrial fibrillation in
the sterile pericarditis model: insights into the mechanism
of its maintenance. Circulation 1997;95:511-21.
62.
Gray RA, Pertsov AM, Jalife J. Incomplete reentry and
epicardial breakthrough patterns during atrial fibrillation
in the sheep heart. Circulation 1996;94:2649-61.
63.
Dorostkar PC, Cheng J, Scheinman MM. Electroanatomical
mapping and ablation of the substrate supporting intraatrial
reentrant tachycardia after palliation for complex congenital
heart disease. Pacing Clin Electrophysiol 1998;21:1810-9.
64.
Konings KTS. Mapping of electrically induced atrial
fibrillation in humans [thesis]. University of Limberg.
Maastricht, Netherlands: 1999.
65.
Ricard P, Levy S, Trigano J, et al. Prospective assessment
of the minimum energy needed for external electrical
cardioversion of atrial fibrillation. Am J Cardiol
1997;79:815-6.
66.
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial
fibrillation begets atrial fibrillation: a study in
awake chronically instrumented goats. Circulation
1995;92:1954-68.
67.
Attuel P, Pellerin D, Gaston J. Latent atrial vulnerability:
new means of electrophysiologic investigations in paroxysmal
atrial arrhythmias. In: Attuel P, Coumel P, Janse MJ,
eds. The Atrium in Health and Disease. Mount
Kisco, NY: Futura Pub, 1989:81-94.
68.
Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical
remodeling of the human atrium: similar effects in patients
with chronic atrial fibrillation and atrial flutter.
J Am Coll Cardiol 1997;30:1785-92.
69.
Olsson SB, Cotoi S, Varnauskas E. Monophasic action
potential and sinus rhythm stability after conversion
of atrial fibrillation. Acta Med Scand 1971;190:381-7.
70.
Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic
remodeling underlying action potential changes in a
canine model of atrial fibrillation. Circ Res
1997;81:512-25.
71.
Fareh S, Benardeau A, Thibault B, Nattel S. The T-type
Ca(2+) channel blocker mibefradil prevents the development
of a substrate for atrial fibrillation by tachycardia-induced
atrial remodeling in dogs. Circulation 1999;100:2191-7.
72.
Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil
reduces tachycardia-induced electrical remodeling of
the atria. Circulation 1997;95:1945-53.
73.
Daoud EG, Marcovitz P, Knight BP, et al. Short-term
effect of atrial fibrillation on atrial contractile
function in humans. Circulation 1999;99:3024-7.
74.
Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial
fibrillation impairs sinus node function in dogs: electrophysiological
remodeling. Circulation 1996;94:2953-60.
75.
Manios EG, Kanoupakis EM, Mavrakis HE, Kallergis EM,
Dermitzaki DN, Vardas PE. Sinus pacemaker function after
cardioversion of chronic atrial fibrillation: is sinus
node remodeling related with recurrence? J Cardiovasc
Electrophysiol 2001;12:800-6.
76. White CW, Kerber RE, Weiss HR,
Marcus ML. The effects of atrial fibrillation on atrial
pressure-volume and flow relationships. Circ Res
1982;51:205-15.
77.
Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett
JC Jr. Atrial stretch, not pressure, is the principal
determinant controlling the acute release of atrial
natriuretic factor. Circ Res 1988;62:191-5.
78.
Spach MS. Nonuniform anisotropic cellular coupling as
a basis for reentrant arrhythmias. In: DiMarco JP, Prystowsky
EN, eds. Atrial Arrhythmias: State of the Art.
Armonk, NY: Futura Pub, 1995:123-47.
79.
Misier AR, Opthof T, van Hemel NM, et al. Increased
dispersion of "refractoriness" in patients with idiopathic
paroxysmal atrial fibrillation. J Am Coll Cardiol
1992;19:1531-5.
80.
Cosio FG, Palacios J, Vidal JM, Cocina EG, Gomez-Sanchez
MA, Tamargo L. Electrophysiologic studies in atrial
fibrillation: slow conduction of premature impulses:
a possible manifestation of the background for reentry.
Am J Cardiol 1983;51:122-30.
81.
Cox JL, Boineau JP, Schuessler RB, Jaquiss RD, Lappas
DG. Modification of the maze procedure for atrial flutter
and atrial fibrillation, I: rationale and surgical results.
J Thorac Cardiovasc Surg 1995;110:473-84.
82.
Cox JL, Jaquiss RD, Schuessler RB, Boineau JP. Modification
of the maze procedure for atrial flutter and atrial
fibrillation, II: surgical technique of the maze III
procedure. J Thorac Cardiovasc Surg 1995;110:485-95.
83.
Elvan A, Pride HP, Eble JN, Zipes DP. Radiofrequency
catheter ablation of the atria reduces inducibility
and duration of atrial fibrillation in dogs. Circulation
1995;91:2235-44.
84.
Klingenheben T, Gronefeld G, Li YG, Hohnloser SH. Heart
rate variability to assess changes in cardiac vagal
modulation prior to the onset of paroxysmal atrial fibrillation
in patients with and without structural heart disease.
ANE 1999;4:19-26.
85.
Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial
fibrillation by ectopic beats originating from the pulmonary
veins: electrophysiological characteristics, pharmacological
responses, and effects of radiofrequency ablation. Circulation
1999;100:1879-86.
86. Coumel P, Attuel P, Leclercq JF,
Friocourt P. Atrial arrhythmias of vagal or catecholaminergic
origin: comparative effects of beta-blocker treatment
and the escape phenomenon [in French]. Arch Mal Coeur
Vaiss 1982;75:373-87.
87. Prystowsky EN. Tachycardia-induced
tachycardia: a mechanism of initiation of atrial fibrillation.
In: DiMarco JP, Prystowsky EN, eds. Atrial Arrhythmias:
State of the Art. Armonk, NY: Futura Pub, 1995:123-49.
88.
Hurwitz JL, German LD, Packer DL, et al. Occurrence
of atrial fibrillation in patients with paroxysmal supraventricular
tachycardia due to atrioventricular nodal reentry. Pacing
Clin Electrophysiol 1990;13:705-10.
89.
Brugada J, Mont L, Matas M, Navarro-Lopez F. Atrial
fibrillation induced by atrioventricular nodal reentrant
tachycardia. Am J Cardiol 1997;79:681-2.
90.
Prystowsky EN. Atrioventricular node reentry: physiology
and radiofrequency ablation. Pacing Clin Electrophysiol
1997;20:552-71.
91.
Mazgalev T, Dreifus LS, Bianchi J, Michelson EL. Atrioventricular
nodal conduction during atrial fibrillation in rabbit
heart. Am J Physiol 1982;243:H754-60.
92.
Page RL, Wharton JM, Prystowsky EN. Effect of continuous
vagal enhancement on concealed conduction and refractoriness
within the atrioventricular node. Am J Cardiol
1996;77:260-5.
93.
Lagendorf R, Pick AL, Katz LN. Ventricular response
in atrial fibrillation: role of concealed conduction
in the AV junction. Circulation 1965;32:69-75.
94.
Page RL, Tang AS, Prystowsky EN. Effect of continuous
enhanced vagal tone on atrioventricular nodal and sinoatrial
nodal function in humans. Circ Res 1991;68:1614-20.
95. Van Den Berg MP, Crijns HJ, Haaksma
J, Brouwer J, Lie KI. Analysis of vagal effects on ventricular
rhythm in patients with atrial fibrillation. Clin
Sci (Colch ) 1994;86:531-5.
96.
Gouaux JL, Ashman R. Auricular fibrillation with aberration
simulating ventricular paroxysmal tachycardia. Am
Heart J 1947;34:366-73.
97.
Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith
WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White
syndrome. N Engl J Med 1979;301:1080-5.
98.
Chen PS, Prystowsky EN. Role of concealed and supernormal
conductions during atrial fibrillation in the preexcitation
syndrome. Am J Cardiol 1991;68:1329-34.
99.
Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman
N. Ventricular fibrillation: a possible mechanism of
sudden death in patients and Wolff-Parkinson-White syndrome.
Circulation 1971;43:520-7.
100.
Prystowsky EN, Benson DW Jr, Fuster V, et al. Management
of patients with atrial fibrillation: a statement for
healthcare professionals from the Subcommittee on Electrocardiography
and Electrophysiology, American Heart Association. Circulation
1996;93:1262-77.
101.
Naito M, David D, Michelson EL, Schaffenburg M, Dreifus
LS. The hemodynamic consequences of cardiac arrhythmias:
evaluation of the relative roles of abnormal atrioventricular
sequencing, irregularity of ventricular rhythm and atrial
fibrillation in a canine model. Am Heart J 1983;106:284-91.
102.
Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic
effects of an irregular sequence of ventricular cycle
lengths during atrial fibrillation. J Am Coll Cardiol
1997;30:1039-45.
103.
Brookes CI, White PA, Staples M, et al. Myocardial contractility
is not constant during spontaneous atrial fibrillation
in patients. Circulation 1998;98:1762-8.
104.
Upshaw CB Jr. Hemodynamic changes after cardioversion
of chronic atrial fibrillation. Arch Intern Med
1997;157:1070-6.
105.
Van Den Berg MP, Tuinenburg AE, van Veldhuisen DJ, De
Kam PJ, Crijns HJ. Cardioversion of atrial fibrillation
in the setting of mild to moderate heart failure. Int
J Cardiol 1998;63:63-70.
106.
Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic
rapid atrial pacing: structural, functional, and electrophysiological
characteristics of a new model of sustained atrial fibrillation.
Circulation 1995;91:1588-95.
107.
Ausma J, Wijffels M, Thone F, Wouters L, Allessie M,
Borgers M. Structural changes of atrial myocardium due
to sustained atrial fibrillation in the goat. Circulation
1997;96:3157-63.
108.
Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial
enlargement as a consequence of atrial fibrillation:
a prospective echocardiographic study. Circulation
1990;82:792-7.
109.
Gosselink AT, Crijns HJ, Hamer HP, Hillege H, Lie KI.
Changes in left and right atrial size after cardioversion
of atrial fibrillation: role of mitral valve disease.
J Am Coll Cardiol 1993;22:1666-72.
110.
Mitusch R, Garbe M, Schmucker G, Schwabe K, Stierle
U, Sheikhzadeh A. Relation of left atrial appendage
function to the duration and reversibility of nonvalvular
atrial fibrillation. Am J Cardiol 1995;75:944-7.
111.
Manning WJ, Silverman DI, Katz SE, et al. Impaired left
atrial mechanical function after cardioversion: relation
to the duration of atrial fibrillation. J Am Coll
Cardiol 1994;23:1535-40.
112.
Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced
cardiomyopathy: a reversible form of left ventricular
dysfunction. Am J Cardiol 1986;57:563-70.
113.
Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular
dysfunction due to atrial fibrillation in patients initially
believed to have idiopathic dilated cardiomyopathy.
Am J Cardiol 1992;69:1570-3.
114.
Philips E, Levine SA. Auricular fibrillation without
other evidence of heart disease: a cause of reversible
heart failure. Am J Med 1949;7:478-89.
115.
Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide
left ventricular ejection fraction after cardioversion
of chronic atrial fibrillation in idiopathic dilated
cardiomyopathy. Eur Heart J 1992;13:1290-5.
116.
Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick
AP, Scheinman MM. Tachycardia-induced cardiomyopathy:
a review of animal models and clinical studies. J
Am Coll Cardiol 1997;29:709-15.
117.
Halperin JL, Hart RG. Atrial fibrillation and stroke:
new ideas, persisting dilemmas. Stroke 1988;19:937-41.
118.
Bogousslavsky J, Van Melle G, Regli F, Kappenberger
L. Pathogenesis of anterior circulation stroke in patients
with nonvalvular atrial fibrillation: the Lausanne Stroke
Registry. Neurology 1990;40:1046-50.
119.
Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart
RG, Anderson DC, for the Stroke Prevention in Atrial
Fibrillation Investigators. Ischemic stroke in patients
with atrial fibrillation: effect of aspirin according
to stroke mechanism. Neurology 1993;43:32-6.
120.
Kanter MC, Tegeler CH, Pearce LA, et al. Carotid stenosis
in patients with atrial fibrillation: prevalence, risk
factors, and relationship to stroke in the Stroke Prevention
in Atrial Fibrillation Study. Arch Intern Med
1994;154:1372-7.
121.
Aschenberg W, Schluter M, Kremer P, Schroder E, Siglow
V, Bleifeld W. Transesophageal two-dimensional echocardiography
for the detection of left atrial appendage thrombus.
J Am Coll Cardiol 1986;7:163-6.
122.
Mugge A, Kuhn H, Nikutta P, Grote J, Lopez JA, Daniel
WG. Assessment of left atrial appendage function by
biplane transesophageal echocardiography in patients
with nonrheumatic atrial fibrillation: identification
of a subgroup of patients at increased embolic risk.
J Am Coll Cardiol 1994;23:599-607.
123.
Chimowitz MI, DeGeorgia MA, Poole RM, Hepner A, Armstrong
WM. Left atrial spontaneous echo contrast is highly
associated with previous stroke in patients with atrial
fibrillation or mitral stenosis. Stroke 1993;24:1015-9.
124.
Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler
evaluation of atrial mechanical function after electrical
cardioversion of atrial fibrillation. J Am Coll Cardiol
1989;13:617-23.
125.
Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical
cardioversion for atrial fibrillation on left atrial
appendage function and spontaneous echo contrast: characterization
by simultaneous transesophageal echocardiography. J
Am Coll Cardiol 1993;22:1359-66.
126.
Fatkin D, Kelly RP, Feneley MP. Relations between left
atrial appendage blood flow velocity, spontaneous echocardiographic
contrast and thromboembolic risk in vivo. J Am Coll
Cardiol 1994;23:961-9.
127.
Daniel WG, Nellessen U, Schroder E, et al. Left atrial
spontaneous echo contrast in mitral valve disease: an
indicator for an increased thromboembolic risk. J
Am Coll Cardiol 1988;11:1204-11.
128.
Hwang JJ, Ko FN, Li YH, et al. Clinical implications
and factors related to left atrial spontaneous echo
contrast in chronic nonvalvular atrial fibrillation.
Cardiology 1994;85:69-75.
129.
Pop GA, Meeder HJ, Roelandt JR, et al. Transthoracic
echo/Doppler in the identification of patients with
chronic non-valvular atrial fibrillation at risk for
thromboembolic events. Eur Heart J 1994;15:1545-51.
130.
Li YH, Lai LP, Shyu KG, Hwang JJ, Kuan P, Lien WP. Clinical
implications of left atrial appendage flow patterns
in nonrheumatic atrial fibrillation. Chest 1994;105:748-52.
131.
Mitusch R, Lange V, Stierle U, Maurer B, Sheikhzadeh
A. Transesophageal echocardiographic determinants of
embolism in nonrheumatic atrial fibrillation. Int
J Card Imaging 1995;11:27-34.
132.
Black IW, Chesterman CN, Hopkins AP, Lee LC, Chong BH,
Walsh WF. Hematologic correlates of left atrial spontaneous
echo contrast and thromboembolism in nonvalvular atrial
fibrillation. J Am Coll Cardiol 1993;21:451-7.
133.
Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left
atrial appendage thrombus is not uncommon in patients
with acute atrial fibrillation and a recent embolic
event: a transesophageal echocardiographic study. J
Am Coll Cardiol 1995;25:452-9.
134.
Manning WJ, Silverman DI, Waksmonski CA, Oettgen P,
Douglas PS. Prevalence of residual left atrial thrombi
among patients with acute thromboembolism and newly
recognized atrial fibrillation. Arch Intern Med
1995;155:2193-8.
135.
Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson
J. Coagulation factors and the increased risk of stroke
in nonvalvular atrial fibrillation. Stroke 1990;21:47-51.
136.
Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic
and haemodynamic abnormalities associated with left
atrial thrombosis in non-rheumatic atrial fibrillation.
Heart 1997;77:407-11.
137.
Lip GY. Hypercoagulability and haemodynamic abnormalities
in atrial fibrillation. Heart 1997;77:395-6.
Comment.
138.
Al-Saady NM, Davies MJ, Luddington LA, et al. Tissue
factor and von Willebrand factor expressions increased
in the atrial tissue of the fibrillating atrium. Circulation
2000;100(suppl I):I-285. Abstract.
139.
Mitusch R. Detection of a hypercoagulable state in nonvalvular
atrial fibrillation and the effect of anticoagulant
therapy. Thromb Haemost 1996;75:219-23.
140.
Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and
beta-thromboglobulin as markers of thrombogenesis and
platelet activation in atrial fibrillation: effects
of introducing ultra-low-dose warfarin and aspirin.
Circulation 1996;94:425-31.
141.
Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin
D-dimer levels in paroxysmal atrial fibrillation: evidence
for intermediate elevated levels of intravascular thrombogenesis.
Am Heart J 1996;131:724-30.
142.
Asakura H, Hifumi S, Jokaji H, et al. Prothrombin fragment
F1 + 2 and thrombin-antithrombin III complex are useful
markers of the hypercoagulable state in atrial fibrillation.
Blood Coagul Fibrinolysis 1992;3:469-73.
143.
Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation
activates platelets and coagulation in a time-dependent
manner: a study in patients with paroxysmal atrial fibrillation.
J Am Coll Cardiol 1997;29:106-12.
144.
Oltrona L, Broccolino M, Merlini PA, Spinola A, Pezzano
A, Mannucci PM. Activation of the hemostatic mechanism
after pharmacological cardioversion of acute nonvalvular
atrial fibrillation. Circulation 1997;95:2003-6.
145.
Yamamoto K, Ikeda U, Seino Y, et al. Coagulation activity
is increased in the left atrium of patients with mitral
stenosis. J Am Coll Cardiol 1995;25:107-12.
146.
Peverill RE, Harper RW, Gelman J, Gan TE, Harris G,
Smolich JJ. Determinants of increased regional left
atrial coagulation activity in patients with mitral
stenosis. Circulation 1996;94:331-9.
147.
Fukazawa H, Yamamoto K, Ikeda U, Shimada K. Effect of
mitral regurgitation on coagulation activity in atrial
fibrillation. Am J Cardiol 1998;81:93-6.
148.
Asinger RW, Koehler J, Pearce LA, et al. Pathophysiologic
correlates of thromboembolism in nonvalvular atrial
fibrillation, II: dense spontaneous echocardiographic
contrast (The Stroke Prevention in Atrial Fibrillation
[SPAF-III] study). J Am Soc Echocardiogr 1999;12:1088-96.
149.
Goldman ME, Pearce LA, Hartz RG, et al. Transesophageal
echocardiographic correlates of clinical risk of thromboembolism
in nonvalvular atrial fibrillation, I: reduced flow
velocity in the left atrial appendage. J Am Soc Echocardiogr
2000;12:1080-7.
150.
Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque
in atrial fibrillation: prevalence, predictors, and
thromboembolic implications. Stroke 1999;30:834-40.
151.
Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion
of nonrheumatic atrial fibrillation: reduced thromboembolic
complications with 4 weeks of precardioversion anticoagulation
are related to atrial thrombus resolution. Circulation
1995;92:160-3.
152.
Hwang JJ, Shyu KG, Hsu KL, Chen JJ, Kuan P, Lien WP.
Significant mitral regurgitation is protective against
left atrial spontaneous echo contrast formation, but
not against systemic embolism. Chest 1994;106:8-12.
153.
Movsowitz C, Movsowitz HD, Jacobs LE, Meyerowitz CB,
Podolsky LA, Kotler MN. Significant mitral regurgitation
is protective against left atrial spontaneous echo contrast
and thrombus as assessed by transesophageal echocardiography.
J Am Soc Echocardiogr 1993;6:107-14.
154.
Blackshear JL, Pearce LA, Asinger RW, et al, for the
Stroke Prevention in Atrial Fibrillation Investigators.
Mitral regurgitation associated with reduced thromboembolic
events in high-risk patients with nonrheumatic atrial
fibrillation. Am J Cardiol 1993;72:840-3.
155.
Hart RG, Pearce LA, Miller VT, et al. Cardioembolic
vs. noncardioembolic strokes in atrial fibrillation:
frequency and effect of antithrombotic agents in the
Stroke Prevention in Atrial Fibrillation studies. Cerebrovasc
Dis 2000;10:39-43.
156.
Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL,
Asinger RW, Hart RG, for the Stroke Prevention in Atrial
Fibrillation III Investigators. Transesophageal echocardiographic
correlates of clinical risk of thromboembolism in nonvalvular
atrial fibrillation. J Am Coll Cardiol 1998;31:1622-6.
157.
Dreslinski GR, Frohlich ED, Dunn FG, Messerli FH, Suarez
DH, Reisin E. Echocardiographic diastolic ventricular
abnormality in hypertensive heart disease: atrial emptying
index. Am J Cardiol 1981;47:1087-90.
158.
Frohlich ED, Apstein C, Chobanian AV, et al. The heart
in hypertension [published erratum appears in N Engl
J Med 1992;327:1768]. N Engl J Med 1992;327:998-1008.
159.
Schmieder RE, Martus P, Klingbeil A. Reversal of left
ventricular hypertrophy in essential hypertension: a
meta-analysis of randomized double-blind studies. JAMA
1996;275:1507-13.
160.
Cushman M, Psaty BM, Macy E, et al. Correlates of thrombin
markers in an elderly cohort free of clinical cardiovascular
disease. Arterioscler Thromb Vasc Biol 1996;16:1163-9.
161.
Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM.
Effects of age, race, sex, and smoking on prothrombin
fragment 1.2 in a healthy population. Clin Chem
1993;39:683-6.
162.
Lowe GD, Rumley A, Woodward M, et al. Epidemiology of
coagulation factors, inhibitors and activation markers:
the Third Glasgow MONICA Survey, I: illustrative reference
ranges by age, sex and hormone use. Br J Haematol
1997;97:775-84.
163.
Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger
RW, for the Stroke Prevention in Atrial Fibrillation
(SPAF) Investigators. Factors associated with ischemic
stroke during aspirin therapy in atrial fibrillation:
analysis of 2012 participants in the SPAF I-III clinical
trials. Stroke 1999;30:1223-9.
164.
Stroke Prevention in Atrial Fibrillation Investigators.
A differential effect of aspirin in the Stroke Prevention
in Atrial Fibrillation Study. J Stroke Cerebrovasc
Dis 1993;3:181-8.
165.
Stroke Prevention in Atrial Fibrillation Investigators.
Predictors of thromboembolism in atrial fibrillation,
I: clinical features of patients at risk. Ann Intern
Med 1992;116:1-5.
166.
Stroke Prevention in Atrial Fibrillation Investigators.
Predictors of thromboembolism in atrial fibrillation,
II: echocardiographic features of patients at risk.
Ann Intern Med 1992;116:6-12.
167.
Echocardiographic predictors of stroke in patients with
atrial fibrillation: a prospective study of 1066 patients
from 3 clinical trials. Arch Intern Med 1998;158:1316-20.
168.
Yoshida M, Nakamura Y, Higashikawa M, Kinoshita M. Predictors
of ischemic stroke in non-rheumatic atrial fibrillation.
Int J Cardiol 1996;56:61-70.
169.
Stollberger C, Chnupa P, Kronik G, et al, for the ELAT
Study Group (Embolism in Left Atrial Thrombi). Transesophageal
echocardiography to assess embolic risk in patients
with atrial fibrillation. Ann Intern Med 1998;128:630-8.
170.
Tsai LM, Lin LJ, Teng JK, Chen JH. Prevalence and clinical
significance of left atrial thrombus in nonrheumatic
atrial fibrillation. Int J Cardiol 1997;58:163-9.
171.
Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial
infarction complicated by atrial fibrillation in the
elderly: prevalence and outcomes. Circulation
2000;101:969-74.
172.
Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification
of a genetic locus for familial atrial fibrillation.
N Engl J Med 1997;336:905-11.
173.
Coumel P. Neural aspects of paroxysmal atrial fibrillation.
In: Falk RH, Podrid PJ, eds. Atrial Fibrillation:
Mechanisms and Management. New York: Raven Press,
1992:109-25.
174.
Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality
of Well-Being scale and NYHA functional status classification
in patients with atrial fibrillation: New York Heart
Association. Am Heart J 1998;135:819-24.
175.
Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett
EL. Quality-of-life assessment in patients with paroxysmal
atrial fibrillation or paroxysmal supraventricular tachycardia.
Am J Cardiol 1994;74:826-9.
176.
Dorian P, Paquette M, Newman D, Green MS, Talajic M,
Roy D. Quality of life improves following treatment
in the Canadian Trial of Atrial Fibrillation. Circulation
1999;100(suppl I):I-502. Abstract.
177.
Greenbaum RA. Oral dofetilide improves quality of life:
an EMERALD substudy. Circulation 1999;100(suppl
I):I-493. Abstract.
178.
Planning and Steering Committees of the AFFIRM study
for the NHLBI AFFIRM investigators. Atrial fibrillation
follow-up investigation of rhythm management: the AFFIRM
study design. Am J Cardiol 1997;79:1198-202.
179.
Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate
control in atrial fibrillation: Pharmacological Intervention
in Atrial Fibrillation (PIAF): a randomised trial. Lancet
2000;356:1789-94.
180.
Marshall HJ, Harris ZI, Griffith MJ, Holder RL, Gammage
MD. Prospective randomized study of ablation and pacing
versus medical therapy for paroxysmal atrial fibrillation:
effects of pacing mode and mode-switch algorithm. Circulation
1999;99:1587-92.
181.
Natale A, Zimerman L, Tomassoni G, et al. AV node ablation
and pacemaker implantation after withdrawal of effective
rate-control medications for chronic atrial fibrillation:
effect on quality of life and exercise performance.
Pacing Clin Electrophysiol 1999;22:1634-9.
182.
Brignole M, Menozzi C, Gianfranchi L, et al. Assessment
of atrioventricular junction ablation and VVIR pacemaker
versus pharmacological treatment in patients with heart
failure and chronic atrial fibrillation: a randomized,
controlled study. Circulation 1998;98:953-60.
183.
Kay GN, Ellenbogen KA, Giudici M, et al, for the APT
Investigators. The Ablate and Pace Trial: a prospective
study of catheter ablation of the AV conduction system
and permanent pacemaker implantation for treatment of
atrial fibrillation. J Interv Card Electrophysiol
1998;2:121-35.
184.
Marshall HJ, Harris ZI, Griffith MJ, Gammage MD. Atrioventricular
nodal ablation and implantation of mode switching dual
chamber pacemakers: effective treatment for drug refractory
paroxysmal atrial fibrillation. Heart 1998;79:543-7.
185.
Brignole M, Gianfranchi L, Menozzi C, et al. Assessment
of atrioventricular junction ablation and DDDR mode-switching
pacemaker versus pharmacological treatment in patients
with severely symptomatic paroxysmal atrial fibrillation:
a randomized controlled study. Circulation 1997;96:2617-24.
186.
Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect
of radiofrequency catheter ablation on health-related
quality of life and activities of daily living in patients
with recurrent arrhythmias. Circulation 1996;94:1585-91.
187.
Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical
outcomes after ablation and pacing therapy for atrial
fibrillation: a meta-analysis. Circulation 2000;101:1138-44.
188.
Anselme F, Saoudi N, Poty H, Douillet R, Cribier A.
Radiofrequency catheter ablation of common atrial flutter:
significance of palpitations and quality-of-life evaluation
in patients with proven isthmus block. Circulation
1999;99:534-40.
189.
Lee SH, Tai CT, Yu WC, et al. Effects of radiofrequency
catheter ablation on quality of life in patients with
atrial flutter. Am J Cardiol 1999;84:278-83.
190.
Gage BF, Cardinalli AB, Owens DK. The effect of stroke
and stroke prophylaxis with aspirin or warfarin on quality
of life. Arch Intern Med 1996;156:1829-36.
191.
Protheroe J, Fahey T, Montgomery AA, Peters TJ. The
impact of patients' preferences on the treatment of
atrial fibrillation: observational study of patient
based decision analysis. BMJ 2000;320:1380-4.
192.
Kerr CR, Boone J, Connolly SJ, et al. The Canadian Registry
of Atrial Fibrillation: a noninterventional follow-up
of patients after the first diagnosis of atrial fibrillation.
Am J Cardiol 1998;82:82N-5N.
193.
Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic
features of chronic atrial fibrillation: the Framingham
study. N Engl J Med 1982;306:1018-22.
194.
Cuddy TE, Connolly SJ. Atrial fibrillation and atrial
flutter. Can J Cardiol 1996;12(suppl A):9A-11A.
195.
Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas
PS. Cardioversion from atrial fibrillation without prolonged
anticoagulation with use of transesophageal echocardiography
to exclude the presence of atrial thrombi. N Engl
J Med 1993;328:750-5.
196.
Krahn AD, Klein GJ, Kerr CR, et al, for the Canadian
Registry of Atrial Fibrillation Investigators. How useful
is thyroid function testing in patients with recent-onset
atrial fibrillation? Arch Intern Med 1996;156:2221-4.
197.
Gillis AM, Klein GJ, MacDonald RG. Investigation of
the patient with atrial fibrillation. Can J Cardiol
1996;12(suppl A):12A-13A.
198.
Seward JB, Khandheria BK, Freeman WK, et al. Multiplane
transesophageal echocardiography: image orientation,
examination technique, anatomic correlations, and clinical
applications. Mayo Clin Proc 1993;68:523-51.
199.
Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic
assessment of the left atrial appendage. J Am Coll
Cardiol 1999;34:1867-77.
200.
Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority
of transesophageal echocardiography in detecting cardiac
source of embolism in patients with cerebral ischemia
of uncertain etiology. J Am Coll Cardiol 1991;17:66-72.
201.
Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal
echocardiography to guide cardioversion in patients
with atrial fibrillation. N Engl J Med 2001;344:1411-20.
202. Leung DY, Black IW, Cranney GB,
Hopkins AP, Walsh WF. Prognostic implications of left
atrial spontaneous echo contrast in nonvalvular atrial
fibrillation. J Am Coll Cardiol 1994;24:755-62.
203.
Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas
PS. Transesophageal echocardiographically facilitated
early cardioversion from atrial fibrillation using short-term
anticoagulation: final results of a prospective 4.5-year
study. J Am Coll Cardiol 1995;25:1354-61.
204.
Klein AL, Grimm RA, Black IW, et al. Cardioversion guided
by transesophageal echocardiography: the ACUTE Pilot
Study: a randomized, controlled trial: Assessment of
Cardioversion Using Transesophageal Echocardiography.
Ann Intern Med 1997;126:200-9.
205.
Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial
thrombus by transesophageal echocardiography does not
preclude embolism after cardioversion of atrial fibrillation:
a multicenter study. Circulation 1994;89:2509-13.
206.
Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart
U. Flecainide versus quinidine for conversion of atrial
fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-8.
207.
Suttorp MJ, Kingma JH, Lie AH, Mast EG. Intravenous
flecainide versus verapamil for acute conversion of
paroxysmal atrial fibrillation or flutter to sinus rhythm.
Am J Cardiol 1989;63:693-6.
208.
Suttorp MJ, Kingma JH, Jessurun ER, Lie AH, van Hemel
NM, Lie KI. The value of class IC antiarrhythmic drugs
for acute conversion of paroxysmal atrial fibrillation
or flutter to sinus rhythm. J Am Coll Cardiol
1990;16:1722-7.
209.
Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol
versus verapamil in the acute treatment of atrial fibrillation
or atrial flutter. Am J Cardiol 1989;63:925-9.
210.
Capucci A, Lenzi T, Boriani G, et al. Effectiveness
of loading oral flecainide for converting recent-onset
atrial fibrillation to sinus rhythm in patients without
organic heart disease or with only systemic hypertension.
Am J Cardiol 1992;70:69-72.
211.
Capucci A, Boriani G, Rubino I, Della CS, Sanguinetti
M, Magnani B. A controlled study on oral propafenone
versus digoxin plus quinidine in converting recent onset
atrial fibrillation to sinus rhythm. Int J Cardiol
1994;43:305-13.
212.
Azpitarte J, Alvarez M, Baun O, et al. Value of single
oral loading dose of propafenone in converting recent-onset
atrial fibrillation: results of a randomized, double-blind,
controlled study. Eur Heart J 1997;18:1649-54.
213.
Kochiadakis GE, Igoumenidis NE, Solomou MC, Kaleboubas
MD, Chlouverakis GI, Vardas PE. Efficacy of amiodarone
for the termination of persistent atrial fibrillation.
Am J Cardiol 1999;83:58-61.
214.
Galve E, Rius T, Ballester R, et al. Intravenous amiodarone
in treatment of recent-onset atrial fibrillation: results
of a randomized, controlled study. J Am Coll Cardiol
1996;27:1079-82.
215.
Falk RH, Pollak A, Singh SN, Friedrich T, for the Intravenous
Dofetilide Investigators. Intravenous dofetilide, a
class III antiarrhythmic agent, for the termination
of sustained atrial fibrillation or flutter. J Am
Coll Cardiol 1997;29:385-90.
216.
Norgaard BL, Wachtell K, Christensen PD, et al, for
the Danish Dofetilide in Atrial Fibrillation and Flutter
Study Group. Efficacy and safety of intravenously administered
dofetilide in acute termination of atrial fibrillation
and flutter: a multicenter, randomized, double-blind,
placebo-controlled trial. Am Heart J 1999;137:1062-9.
217.
Peuhkurinen K, Niemela M, Ylitalo A, Linnaluoto M, Lilja
M, Juvonen J. Effectiveness of amiodarone as a single
oral dose for recent-onset atrial fibrillation. Am
J Cardiol 2000;85:462-5.
218.
Kerin NZ, Faitel K, Naini M. The efficacy of intravenous
amiodarone for the conversion of chronic atrial fibrillation:
amiodarone vs quinidine for conversion of atrial fibrillation.
Arch Intern Med 1996;156:49-53.
219.
Zehender M, Hohnloser S, Muller B, Meinertz T, Just
H. Effects of amiodarone versus quinidine and verapamil
in patients with chronic atrial fibrillation: results
of a comparative study and a 2-year follow-up. J
Am Coll Cardiol 1992;19:1054-9.
220.
Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY.
Intravenous flecainide versus amiodarone for recent-onset
atrial fibrillation. Am J Cardiol 1995;75:693-7.
221.
Bertini G, Conti A, Fradella G, et al. Propafenone versus
amiodarone in field treatment of primary atrial tachydysrhythmias.
J Emerg Med 1990;8:15-20.
222.
Hou ZY, Chang MS, Chen CY, et al. Acute treatment of
recent-onset atrial fibrillation and flutter with a
tailored dosing regimen of intravenous amiodarone: a
randomized, digoxin-controlled study. Eur Heart J
1995;16:521-8.
223.
Opolski G, Stanislawska J, Gorecki A, Swiecicka G, Torbicki
A, Kraska T. Amiodarone in restoration and maintenance
of sinus rhythm in patients with chronic atrial fibrillation
after unsuccessful direct-current cardioversion. Clin
Cardiol 1997;20:337-40.
224.
Noc M, Stajer D, Horvat M. Intravenous amiodarone versus
verapamil for acute conversion of paroxysmal atrial
fibrillation to sinus rhythm. Am J Cardiol 1990;65:679-80.
225.
Tieleman RG, Gosselink AT, Crijns HJ, et al. Efficacy,
safety, and determinants of conversion of atrial fibrillation
and flutter with oral amiodarone. Am J Cardiol
1997;79:53-7.
226.
Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion
of atrial fibrillation with intravenous dofetilide.
Int J Cardiol 1995;49:159-66.
227.
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al,
for the Danish Investigations of Arrhythmia and Mortality
on Dofetilide Study Group. Dofetilide in patients with
congestive heart failure and left ventricular dysfunction.
N Engl J Med 1999;341:857-65.
228.
Lindeboom JE, Kingma JH, Crijns HJ, Dunselman PH. Efficacy
and safety of intravenous dofetilide for rapid termination
of atrial fibrillation and atrial flutter. Am J Cardiol
2000;85:1031-3.
229.
Botto GL, Bonini W, Broffoni T, et al. Regular ventricular
rhythms before conversion of recent onset atrial fibrillation
to sinus rhythm. Pacing Clin Electrophysiol 1994;17:2114-7.
230.
Botto GL, Capucci A, Bonini W, et al. Conversion of
recent onset atrial fibrillation to sinus rhythm using
a single oral loading dose of propafenone: comparison
of two regimens. Int J Cardiol 1997;58:55-61.
231.
Donovan KD, Dobb GJ, Coombs LJ, et al. Reversion of
recent-onset atrial fibrillation to sinus rhythm by
intravenous flecainide. Am J Cardiol 1991;67:137-41.
232.
Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy
of flecainide in patients with supraventricular arrhythmias
and respiratory insufficiency. Intensive Care Med
1994;20:42-4.
233.
Baldi N, Russo VA, Lenti V, et al. Relation between
plasma levels and efficacy of flecainide and propafenone
for treatment of atrial fibrillation of recent onset.
New Trends Arrhythmias 1993;9:899-906.
234.
Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic
actions of intravenous ibutilide compared with procainamide
during human atrial flutter and fibrillation: electrophysiological
determinants of enhanced conversion efficacy. Circulation
1997;96:4298-306.
235.
Guo GB, Ellenbogen KA, Wood MA, Stambler BS. Conversion
of atrial flutter by ibutilide is associated with increased
atrial cycle length variability. J Am Coll Cardiol
1996;27:1083-9.
236.
Volgman AS, Carberry PA, Stambler B, et al. Conversion
efficacy and safety of intravenous ibutilide compared
with intravenous procainamide in patients with atrial
flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-9.
237.
Vos MA, Golitsyn SR, Stangl K, et al, for the Ibutilide/Sotalol
Comparator Study Group. Superiority of ibutilide (a
new class III agent) over dl-sotalol in converting atrial
flutter and atrial fibrillation. Heart 1998;79:568-75.
238.
Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield
LK, VanderLugt JT, for the Ibutilide Repeat Dose Study
Investigators. Efficacy and safety of repeated intravenous
doses of ibutilide for rapid conversion of atrial flutter
or fibrillation. Circulation 1996;94:1613-21.
239.
Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy
of intravenous ibutilide for rapid termination of atrial
fibrillation and atrial flutter: a dose-response study
[published erratum appears in J Am Coll Cardiol 1996;28:1082].
J Am Coll Cardiol 1996;28:130-6.
240.
Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani
B. Propafenone for conversion of recent-onset atrial
fibrillation: a controlled comparison between oral loading
dose and intravenous administration. Chest 1995;108:355-8.
241.
Boriani G, Biffi M, Capucci A, et al. Oral propafenone
to convert recent-onset atrial fibrillation in patients
with and without underlying heart disease: a randomized,
controlled trial. Ann Intern Med 1997;126:621-5.
242.
Fresco C, Proclemer A, Pavan A, et al, for the Paroxysmal
Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators.
Intravenous propafenone in paroxysmal atrial fibrillation:
a randomized, placebo-controlled, double-blind, multicenter
clinical trial. Clin Cardiol 1996;19:409-12.
243.
Stroobandt R, Stiels B, Hoebrechts R, for the Propafenone
Atrial Fibrillation Trial Investigators. Propafenone
for conversion and prophylaxis of atrial fibrillation.
Am J Cardiol 1997;79:418-23.
244.
Bellandi F, Cantini F, Pedone T, Palchetti R, Bamoshmoosh
M, Dabizzi RP. Effectiveness of intravenous propafenone
for conversion of recent-onset atrial fibrillation:
a placebo-controlled study. Clin Cardiol 1995;18:631-4.
245.
Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M,
Santini M. Effects of oral propafenone administration
before electrical cardioversion of chronic atrial fibrillation:
a placebo-controlled study. J Am Coll Cardiol
1996;28:700-6.
246.
Weiner P, Ganam R, Zidan F, Rabner M. Clinical course
of recent-onset atrial fibrillation treated with oral
propafenone. Chest 1994;105:1013-6.
247.
Di Benedetto S. Quinidine versus propafenone for conversion
of atrial fibrillation to sinus rhythm. Am J Cardiol
1997;80:518-9.
248.
Vita JA, Friedman PL, Cantillon C, Antman EM. Efficacy
of intravenous propafenone for the acute management
of atrial fibrillation. Am J Cardiol 1989;63:1275-8.
249.
Barroffio R, Tisi G, Guzzini F, Milvio E, Annoni P.
A randomised study comparing digoxin and propafenone
in the treatment of recent onset atrial fibrillation.
Clin Drug Invest 1995;9:277-83.
250.
Hohnloser SH, van de LA, Baedeker F. Efficacy and proarrhythmic
hazards of pharmacologic cardioversion of atrial fibrillation:
prospective comparison of sotalol versus quinidine.
J Am Coll Cardiol 1995;26:852-8.
251.
Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison
of sotalol with digoxin-quinidine for conversion of
acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine
Trial). Am J Cardiol 1995;76:495-8.
252.
Pilati G, Lenzi T, Trisolino G, et al. Amiodarone versus
quinidine for conversion of recent onset atrial fibrillation
to sinus rhythm. Curr Ther Res 1991;49:140-6.
253.
Sweany AE, Moncloa F, Vickers FF, Zupkis RV. Antiarrhythmic
effects of intravenous timolol in supraventricular arrhythmias.
Clin Pharmacol Ther 1985;37:124-7.
254.
Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG,
Tsapas G. Intravenous administration of diltiazem in
the treatment of supraventricular tachyarrhythmias.
Acta Cardiol 1995;50:125-34.
255.
Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli
NJ. Digoxin for converting recent-onset atrial fibrillation
to sinus rhythm: a randomized, double-blinded trial.
Ann Intern Med 1987;106:503-6.
256.
Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen
YW, for the Sotalol Study Group. Efficacy and safety
of sotalol in digitalized patients with chronic atrial
fibrillation. Am J Cardiol 1991;68:1227-30.
257.
Jordaens L. Conversion of atrial fibrillation to sinus
rhythm and rate control by digoxin in comparison to
placebo. Eur Heart J 1997;18:643-8.
258.
The Digitalis in Acute Atrial Fibrillation (DAAF) Trial
Group. Intravenous digoxin in acute atrial fibrillation:
results of a randomized, placebo-controlled multicentre
trial in 239 patients. Eur Heart J 1997;18:649-54.
259.
Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L,
Costa A. Comparison of flecainide and procainamide in
cardioversion of atrial fibrillation. Eur Heart J
1993;14:1127-31.
260.
Sung RJ, Tan HL, Karagounis L, et al, for the Sotalol
Multicenter Study Group. Intravenous sotalol for the
termination of supraventricular tachycardia and atrial
fibrillation and flutter: a multicenter, randomized,
double-blind, placebo-controlled study. Am Heart
J 1995;129:739-48.
261.
Singh S, Zoble RG, Yellen L, et al. Efficacy and safety
of oral dofetilide in converting to and maintaining
sinus rhythm in patients with chronic atrial fibrillation
or atrial flutter: the Symptomatic Atrial Fibrillation
Investigative Research on Dofetilide (SAFIRE-D) study.
Circulation 2000;102:2385-90.
262.
Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis
AM, Simantirakis EN, Chlouverakis GI. Amiodarone as
a first-choice drug for restoring sinus rhythm in patients
with atrial fibrillation: a randomized, controlled study.
Chest 2000;117:1538-45.
263.
Hou CJ, Chang-Sing P, Flynn E, et al. Determination
of ventricular vulnerable period and ventricular fibrillation
threshold by use of T-wave shocks in patients undergoing
implantation of cardioverter/defibrillators. Circulation
1995;92:2558-64.
264.
Ewy GA. The optimal technique for electrical cardioversion
of atrial fibrillation. Clin Cardiol 1994;17:79-84.
265.
Dalzell GW, Cunningham SR, Anderson J, Adgey AA. Electrode
pad size, transthoracic impedance and success of external
ventricular defibrillation. Am J Cardiol 1989;64:741-4.
266.
Connell PN, Ewy GA, Dahl CF, Ewy MD. Transthoracic impedance
to defibrillator discharge: effect of electrode size
and electrode-chest wall interface. J Electrocardiol
1973;6:313-M.
267.
Kerber RE, Jensen SR, Grayzel J, Kennedy J, Hoyt R.
Elective cardioversion: influence of paddle-electrode
location and size on success rates and energy requirements.
N Engl J Med 1981;305:658-62.
268.
Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion
of atrial fibrillation: comparison of rectilinear biphasic
versus damped sine wave monophasic shocks. Circulation
2000;101:1282-7.
269.
Lown B, Amarasingham R, Neuman J. New method for terminating
cardiac arrhythmias: use of synchronized capacitor discharge.
JAMA 1962;182:548-55.
270.
Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. Cardioversion
of atrial fibrillation: a report on the treatment of
65 episodes in 50 patients. N Engl J Med 1963;269:325-31.
271.
Kerber RE, Martins JB, Kienzle MG, et al. Energy, current,
and success in defibrillation and cardioversion: clinical
studies using an automated impedance-based method of
energy ad | 
